Scott Bizily - Net Worth and Insider Trading
Scott Bizily Net Worth
The estimated net worth of Scott Bizily is at least $24,949 dollars as of 2023-10-04. Scott Bizily is the Chief Legal and HR Officer of 4D Molecular Therapeutics Inc and owns about 2,109 shares of 4D Molecular Therapeutics Inc (FDMT) stock worth over $24,949. Details can be seen in Scott Bizily's Latest Holdings Summary section.
Transaction Summary of Scott Bizily
Scott Bizily Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Scott Bizily owns 1 companies in total, including 4D Molecular Therapeutics Inc (FDMT) .
Scott Bizily Latest Holdings Summary
Scott Bizily currently owns a total of 1 stock. Scott Bizily owns 2,109 shares of 4D Molecular Therapeutics Inc (FDMT) as of April 21, 2023, with a value of $24,949.
Scott Bizily Form 4 Trading Tracker
According to the SEC Form 4 filings, Scott Bizily has made a total of 3 transactions in 4D Molecular Therapeutics Inc (FDMT) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in 4D Molecular Therapeutics Inc is the sale of 3,750 shares on April 21, 2023, which brought Scott Bizily around $75,000.
Insider Trading History of Scott Bizily
Scott Bizily Trading Performance
Scott Bizily Ownership Network
Ownership Network List of Scott Bizily
Ownership Network Relation of Scott Bizily
Scott Bizily Owned Company Details
What does 4D Molecular Therapeutics Inc do?
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
Who are the key executives at 4D Molecular Therapeutics Inc?
Scott Bizily is the Chief Legal and HR Officer of 4D Molecular Therapeutics Inc. Other key executives at 4D Molecular Therapeutics Inc include 10 percent owner Viking Global Opportunities Parent Gp Llc , 10 percent owner Viking Global Investors Lp , and 10 percent owner Ole Andreas Halvorsen .
4D Molecular Therapeutics Inc (FDMT) Insider Trades Summary
Over the past 18 months, Scott Bizily made 3 insider transaction in 4D Molecular Therapeutics Inc (FDMT) with a net sale of 11,998. Other recent insider transactions involving 4D Molecular Therapeutics Inc (FDMT) include a net sale of 140,847 shares made by David Kirn , a net purchase of 850,000 shares made by Viking Global Investors Lp , and a net sale of 5,000 shares made by Jacob Chacko .
In summary, during the past 3 months, insiders sold 0 shares of 4D Molecular Therapeutics Inc (FDMT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 157,845 shares of 4D Molecular Therapeutics Inc (FDMT) were sold and 850,000 shares were bought by its insiders, resulting in a net purchase of 692,155 shares.
4D Molecular Therapeutics Inc (FDMT)'s detailed insider trading history can be found in Insider Trading Tracker table.
4D Molecular Therapeutics Inc Insider Transactions
Scott Bizily Mailing Address
Above is the net worth, insider trading, and ownership report for Scott Bizily. You might contact Scott Bizily via mailing address: C/o 4d Molecular Therapeutics, Inc., 5858 Horton Street #455, Emeryville Ca 94608.